Geron Corporation, an advanced stage clinical biopharmaceutical company, focuses on the development and commercialization of therapies for myeloid hematologic neoplasms. The company is headquartered in Foster City, California.
| Revenue (TTM) | $196.12M |
| Gross Profit (TTM) | $119.57M |
| EBITDA | $-34.61M |
| Operating Margin | -0.46% |
| Return on Equity | -27.10% |
| Return on Assets | -4.00% |
| Revenue/Share (TTM) | $0.29 |
| Book Value | $0.36 |
| Price-to-Book | 4.14 |
| Price-to-Sales (TTM) | 4.74 |
| EV/Revenue | 3.871 |
| EV/EBITDA | -9.06 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 30.90% |
| Shares Outstanding | $641.52M |
| Float | $535.70M |
| % Insiders | 0.08% |
| % Institutions | 79.92% |
Volatility is currently contracting
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective July 17, 2026, it granted stock options to purchase an aggregate of 202,500 shares of common stock to five newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
FOSTER CITY, Calif., July 22, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that it will release its second quarter 2026 financial results and business highlights before the market opens on Wednesday, August 5, 2026, via press release, which will be available on the Investors and Media section of the Company's website. Geron will host a conference call and webcast at 8:00 a.m. Eastern Time.
CAMBRIDGE, Mass., July 15, 2026 (GLOBE NEWSWIRE) -- Rectify Pharmaceuticals, a biotechnology company advancing Positive Functional Modulators (PFMs), a novel class of oral small molecules designed to restore and enhance membrane protein function, today announced the appointment of Constantine Chinoporos as Executive Chairman of the company's board of directors, effective immediately.
FOSTER CITY, Calif., July 14, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that it granted an equity award in the form of a stock option to purchase 1,700,000 shares of Geron common stock to Chinmaya Rath, Geron's new Chief Business Officer, as an inducement material to his acceptance of employment with Geron.
Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies Mr. Rath brings senior leadership experience in business development across a range of biopharmaceutical companies
Geron Corporation delivered Q1'26 Rytelo revenues of $51.8M, up 8% sequentially, with two consecutive quarters of demand growth. GERN maintained 2026 guidance, with net product revenues of $220M-$240M expected. Management is now prioritizing high-volume community accounts, aiming to shift sales mix from academic centers to the broader 80% community-driven market.
FOSTER CITY, Calif., June 18, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial stage biopharmaceutical company, today reported that, effective June 17, 2026, it granted stock options to purchase an aggregate of 690,000 shares of common stock to eight newly hired employees as an inducement material to such employees' acceptance of employment with Geron.
Geron Corporation (GERN) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Geron (GERN) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
FOSTER CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that members of the management team are scheduled to participate in a fireside chat at the Goldman Sachs 47th Annual Global Healthcare Conference on Monday, June 8, 2026 at 8:40 a.m.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on GERN and any ticker you trade — then tracks every position and per-strategy win rate.
